Brevan Howard Capital Management
IMNM icon

Brevan Howard Capital Management’s Immunome IMNM Stock Holding History

Brevan Howard Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$535K Buy
25,267
+3,989
+19% +$85.4K ﹤0.01% 1413
2026
Q1 		$465K Buy
+21,278
New +$474K ﹤0.01% 1343
2024
Q2 		– Sell
-31,878
Closed -$787K – 1204
2024
Q1 		$787K Buy
+31,878
New +$647K 0.01% 332

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Brevan Howard Capital Management's IMNM Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Immunome (IMNM) stake by 19% in Q2 2026, buying an estimated $85.4K and bringing the position to 25,267 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Brevan Howard Capital Management first reported a position in IMNM in Q1 2024 and has held it in 3 quarters since. The position peaked at $787K in Q1 2024. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Brevan Howard Capital Management held 25,267 shares of Immunome worth $535K as of Q2 2026.
  • Brevan Howard Capital Management bought 3,989 Immunome shares in Q2 2026, an estimated $85.4K.
  • Immunome made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1413 holding.
  • Brevan Howard Capital Management first reported a position in Immunome in Q1 2024 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Immunome position peaked at $787K in Q1 2024.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.